The price of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares last traded on Wall Street rose 6.85% to $0.72.
LXRX stock price is now -40.46% away from the 50-day moving average and -57.15% away from the 200-day moving average. The market capitalization of the company currently stands at $261.57M.
With the price target of $10, H.C. Wainwright recently initiated with Buy rating for Lexicon Pharmaceuticals Inc (NASDAQ: LXRX). On April 30, 2024, Leerink Partners recently initiated its ‘Outperform’ rating on the stock quoting a target price of $5, while ‘Jefferies’ rates the stock as ‘Hold’
In other news, COATS LONNEL, Former Affiliate bought 300,000 shares of the company’s stock on Aug 15 ’24. The stock was bought for $480,000 at an average price of $1.60. A total of 53.33% of the company’s stock is owned by insiders.
During the past 12 months, Lexicon Pharmaceuticals Inc has had a low of $0.62 and a high of $3.73. As of last week, the company has a debt-to-equity ratio of 0.59, a current ratio of 7.45, and a quick ratio of 7.43. The fifty day moving average price for LXRX is $1.2218 and a two-hundred day moving average price translates $1.68765 for the stock.
The latest earnings results from Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was released for 2024-09-30. The net profit margin was -4109.41% and return on equity was -135.14% for LXRX. The company reported revenue of $1.75 million for the quarter, compared to $0.16 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 980.25 percent.
